Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.

Front Immunol · 2022 · PMC9845912 · PMID 36685524

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

First, we analysed efficacy-associated stops and confirmed – by univariate analysis – the prognostic impact of baseline SLEDAI-2K and PGA, whereas inflammatory rash (p=0.053) and concomitant use of immunosuppressives (p=0.079) did not reach statistical significance ( Supplementary Table S5 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.